نمایش پرونده ساده آیتم

dc.contributor.authorGoudarzi, M
dc.contributor.authorSeyedjavadi, SS
dc.contributor.authorGoudarzi, H
dc.contributor.authorMehdizadeh Aghdam, E
dc.contributor.authorNazeri, S
dc.date.accessioned2018-08-26T06:04:49Z
dc.date.available2018-08-26T06:04:49Z
dc.date.issued2014
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/41581
dc.description.abstractThe incidence and mortality rate of Clostridium difficile infection have increased remarkably in both hospital and community settings during the last two decades. The growth of infection may be caused by multiple factors including inappropriate antibiotic usage, poor standards of environmental cleanliness, changes in infection control practices, large outbreaks of C. difficile infection in hospitals, alteration of circulating strains of C. difficile, and spread of hypervirulent strains. Detection of high-risk populations could be helpful for prompt diagnosis and consequent treatment of patients suffering from C. difficile infection. Metronidazole and oral vancomycin are recommended antibiotics for the treatment of initial infection. Current treatments for C. difficile infection consist of supportive care, discontinuing the unnecessary antibiotic, and specific antimicrobial therapy. Moreover, novel approaches include fidaxomicin therapy, monoclonal antibodies, and fecal microbiota transplantation mediated therapy. Fecal microbiota transplantation has shown relevant efficacy to overcome C. difficile infection and reduce its recurrence.
dc.language.isoEnglish
dc.relation.ispartofScientifica
dc.titleClostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options.
dc.typearticle
dc.citation.volume2014
dc.citation.spage916826
dc.citation.indexPubmed
dc.identifier.DOIhttps://doi.org/10.1155/2014/916826


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم